Lalwani Nikhil 4

What Happened

• Nikhil Lalwani, President & CEO (and Director) of ANI Pharmaceuticals, received a restricted stock award of 75,592 shares on 2026-02-26 valued at $77.15 per share (total ~$5,831,923). Two days later (2026-02-28) 12,217 shares were disposed to satisfy tax withholding obligations at $73.90 per share (total ~$902,836). The award (code A) is an acquisition of restricted stock; the withholding (code F) is not an open-market sale but tax-related disposal.

Key Details

• Transaction dates and prices:
  • 2026-02-26: Award of 75,592 shares @ $77.15 (value ~$5,831,923).
  • 2026-02-28: 12,217 shares withheld/disposed @ $73.90 (value ~$902,836) to cover taxes.
• Shares owned after transaction: Not specified in the summary provided — see the full Form 4 for total beneficial ownership.
• Footnotes:
  • F1: The 75,592-share restricted stock award vests in four equal annual installments starting on Feb 26, 2026.
  • F2: The 12,217 shares were withheld for tax purposes; the filing notes withholding is exempt under Rule 16(b)-3 in connection with the vesting of previously granted restricted stock (23,883 shares referenced).
• Filing timeliness: Form 4 was filed on 2026-03-02 for a 2026-02-26 grant; this falls within the standard two-business-day reporting window.

Context

• This was a restricted stock grant (not an open-market purchase). Restricted awards are common as executive compensation and vest over time; the withholding action is a routine tax-related disposition rather than a discretionary sale. For full ownership and longer-term context, check the complete Form 4 and prior filings.